Curated News
By: NewsRamp Editorial Staff
September 16, 2025
Psylutions CEO Warns of Risks in Unregulated Psychedelic Edibles Market
TLDR
- Psylutions gains competitive advantage through rigorous third-party testing and transparent labeling, ensuring reliable psilocybin products that build consumer trust and market leadership.
- Psylutions implements strict quality controls with third-party laboratory testing to verify precise psilocybin content in milligrams, ensuring consistency and accurate potency labeling.
- Regulated psychedelic pathways with transparent labeling protect patient safety and build trust, advancing responsible medicine that prioritizes public health and wellbeing.
- Scientific American found magic mushroom edibles often contain no psilocybin, highlighting the importance of verified products and accurate potency labeling.
Impact - Why it Matters
This news matters because it exposes critical safety gaps in the rapidly growing psychedelic medicine industry, where unregulated products can pose serious health risks due to mislabeling, undisclosed ingredients, or complete absence of advertised compounds. For consumers seeking therapeutic benefits from psilocybin, these issues could lead to ineffective treatment, adverse reactions, or legal complications. The push for regulated pathways and transparent practices, as advocated by Psylutions, is essential to ensure patient safety, build trust, and support the responsible integration of psychedelics into healthcare, potentially affecting millions exploring alternative mental health treatments.
Summary
In response to a concerning Scientific American report that revealed several "magic mushroom" edibles contained no psilocybin and sometimes undisclosed synthetic substances, Psylutions Founder & CEO Rhonda DeSantis issued a strong statement emphasizing the critical need for regulation and transparency in the psychedelic medicine industry. The report, which tested products sold in Portland, found that most contained no psilocybin and at least one undisclosed active ingredient, highlighting significant consumer safety risks in unregulated markets.
DeSantis pointed out that even when products do contain psilocybin, misleading labeling creates dangerous confusion—products labeled by dry weight (e.g., 4,000 mg) rather than actual psilocybin content in milligrams make potency unpredictable and unsafe. Psylutions addresses these issues through rigorous third-party laboratory testing, strict quality controls, and transparent labeling that specifies active compound potency. As Colorado's first state-licensed psilocybin cultivator and manufacturer, the company serves licensed healing centers, clinicians, and researchers with precision-grown, lab-verified therapies, setting new standards for safety and reliability in the emerging psychedelics field.
Source Statement
This curated news summary relied on content disributed by Newsworthy.ai. Read the original source here, Psylutions CEO Warns of Risks in Unregulated Psychedelic Edibles Market
